Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant.
about
Structure-based analysis of the herpes simplex virus glycoprotein D binding site present on herpesvirus entry mediator HveA (HVEM).Poxvirus pathogenesisOncolytic virotherapy using herpes simplex virus: how far have we come?Transgenic cell lines for detection of animal viruses2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (1110U81) potently inhibits human cytomegalovirus replication and potentiates the antiviral effects of ganciclovirThe C-terminal 25 amino acids of the protease and its substrate ICP35 of herpes simplex virus type 1 are involved in the formation of sealed capsidsThe herpes simplex virus type 1 cleavage/packaging protein, UL32, is involved in efficient localization of capsids to replication compartmentsDetection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2.Inhibition of herpes simplex virus gD and lymphotoxin-alpha binding to HveA by peptide antagonists.Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases.Identification of candidate gammaherpesvirus 68 genes required for virus replication by signature-tagged transposon mutagenesis.Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infectionAnti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma.B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cellsAltered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysisHerpes simplex virus oncolytic therapy for pediatric malignanciesThe PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for immediate-early gene expression and virus growthTissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitorsAttenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates.The major neutralizing antigenic site on herpes simplex virus glycoprotein D overlaps a receptor-binding domain.2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir.Efficient activation of viral genomes by levels of herpes simplex virus ICP0 insufficient to affect cellular gene expression or cell survival.Herpes simplex virus ICP27 activation of stress kinases JNK and p38.Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus.Conditionally replicating herpes vectors for cancer therapy.Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applicationsTargeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells.Molecular imaging with bioluminescence and PET reveals viral oncolysis kinetics and tumor viability.Radiation inactivation of ribonucleotide reductase, an enzyme with a stable free radical.The cyclin-dependent kinase inhibitor roscovitine inhibits the transactivating activity and alters the posttranslational modification of herpes simplex virus type 1 ICP0.Assembly of an active translation initiation factor complex by a viral protein.Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47deltaOncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines.Specific inhibition of herpes simplex virus DNA polymerase by helical peptides corresponding to the subunit interfaceMultimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis.Resistance of mRNA translation to acute endoplasmic reticulum stress-inducing agents in herpes simplex virus type 1-infected cells requires multiple virus-encoded functions.Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors.Identity of zinc finger nucleases with specificity to herpes simplex virus type II genomic DNA: novel HSV-2 vaccine/therapy precursorsRetrograde axonal transport of herpes simplex virus: evidence for a single mechanism and a role for tegument
P2860
Q24538731-6EC9DD00-E140-4CA9-9C6C-7B7B7273A3F9Q24634729-0A805474-1E5E-47F1-80FB-E7C6C5FF400EQ26862461-0AB08D62-F138-44DF-843F-B25E296FDB9FQ27477859-A66A7591-19C8-4B47-82F1-9D5CC0B28E62Q28378622-DDFC2717-321F-428D-AB55-02ECC725FC47Q30452629-CAA26799-4BD1-4D39-A50A-A46243112768Q30453534-E98E36BF-8A1F-4AB1-9E63-E7D010854FD9Q30501507-074EF6A1-B48E-4849-9691-FA51C55C7573Q30712456-BF76950F-D7F2-48A8-8C23-C70BC9FCF847Q30826113-DAC80C8C-4268-49A9-A785-6AC0CF265BF0Q33206815-CD8BE618-329D-4086-BF00-BD4DA3C2A04DQ33395218-26050F39-5507-47EF-8EE8-4C7FCD933EE6Q33579396-16C5A99C-EAF3-4C93-B263-89A38621D2A7Q33649894-5762CC57-37AE-4859-AB6C-F078C10697A1Q33675567-8A970837-507F-48FE-A863-C6813B59BF89Q33713824-9C5465C9-4A3B-4839-972B-B41E95CDCB6EQ33785400-0FF4D85F-9217-40F7-9AC0-28636A83C799Q33794302-5C438B51-508F-4F6B-AED9-5C20D69EFF8DQ33816579-0D3AB118-0633-449E-8790-784914132161Q33824681-D9E93C6A-7770-40B1-B92D-D4F5F823410AQ33836051-6074E29F-5E33-423D-A63B-4D9ACE905ACFQ33838501-4061C4A3-E580-4CF9-B5D6-F947889702F6Q33843399-8B68B1C2-9829-4850-9E26-CF062160FC04Q33844465-79048B9B-5CB0-4EF8-8166-0925E4106C06Q33882697-523994E1-BCC5-40F3-B9EE-8EDA24F031DEQ33995471-87193782-8C5E-443C-8DC7-17C7A4BDF857Q33995752-476DAA1B-69EC-4CC1-AA0E-5DAB01564A95Q34073330-23D3A085-1924-4DFE-8E6E-56B1283241BEQ34099721-9F50B563-4FF5-4728-B4B3-E00F154E18FCQ34174145-2CF8F057-A11A-496F-A9BD-619A4EA1ACF1Q34330457-B8E2B002-33FB-4628-80A5-671D8400DA73Q34360252-AEFC8782-4466-4C6E-9DC1-385C991B8A95Q34423157-98D8027C-4F83-41E7-9CE5-5546099FF5C6Q34557399-16DBE452-BD18-49B3-A4BE-8EB473A4F399Q34621250-260898ED-D45A-4186-AD55-F4CEB8C16F84Q34928710-C34DC507-0CA6-4161-B986-4BB53749E151Q35023672-1066DC84-8AE6-4153-95CA-220D0DA43F31Q35023693-2AF480CA-9015-41E8-BDF1-1650EBCD8064Q35111489-F073F7E3-EDA3-43F9-8FAC-64E0476E0B58Q35177798-DCA705FF-CDF4-4F2B-AFAE-174BCB88C87F
P2860
Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Herpes simplex virus type 1-in ...... an ICP6 lacZ insertion mutant.
@en
type
label
Herpes simplex virus type 1-in ...... an ICP6 lacZ insertion mutant.
@en
prefLabel
Herpes simplex virus type 1-in ...... an ICP6 lacZ insertion mutant.
@en
P2860
P1433
P1476
Herpes simplex virus type 1-in ...... an ICP6 lacZ insertion mutant.
@en
P2093
D J Goldstein
S K Weller
P2860
P304
P407
P577
1988-01-01T00:00:00Z